Open AccessLithium chloride ameliorates cognition dysfunction induced by sevoflurane anesthesia in rats
Author(s) -
Wang Yilong,
An Xiaohu,
Zhang Xiaoqing,
Liu Jianhui,
Wang Jianwei,
Yang Zeyong
Publication year - 2020
Publication title -
febs open bio
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.718
H-Index - 31
ISSN - 2211-5463
DOI - 10.1002/2211-5463.12779
Subject(s) - oxidative stress , neuroprotection , lithium (medication) , sevoflurane , medicine , postoperative cognitive dysfunction , lithium chloride , gsk 3 , hippocampal formation , anesthesia , glycogen synthase , pharmacology , apoptosis , endocrinology , cognition , chemistry , kinase , glycogen , biochemistry , psychiatry , organic chemistry
Postoperative cognitive dysfunction is a common complication in elderly patients after surgeries involving anesthesia, but the underlying mechanisms are poorly understood. Lithium is a conventional treatment for bipolar disorder, which exerts a neuroprotective role in various diseases by inhibiting glycogen synthase kinase‐3β (GSK‐3β) in the brain and spinal cord. However, it is not known whether lithium chloride (LiCl) can protect against cognitive dysfunction induced by sevoflurane (SEV) anesthesia. Here, we examined the effects of LiCl on SEV‐induced cognitive dysfunction in rats and on SEV‐induced neuron apoptosis. We report that anesthesia with SEV significantly impaired memory performance, induced oxidative stress and hippocampal neuron apoptosis, and stimulated GSK‐3β activity. Treatment with LiCl ameliorated SEV‐induced cognitive disorder in rats by inhibiting the GSK‐3β/β‐catenin signaling pathway. In addition, LiCl reduced hippocampal neuron apoptosis and oxidative stress induced by SEV anesthesia. These results suggest that LiCl may have potential for development into a therapeutic agent for treatment of SEV anesthesia‐induced cognitive dysfunction.